| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $688K | -36.1% | -12.3% |
| SG&A Expense | $2.0M | -23.0% | +22.1% |
| Operating Income | -$2.7M | +26.8% | -11.1% |
| Net Income | -$2.7M | +26.8% | -11.5% |
| EPS (Basic) | -$1.31 | +29.9% | +39.9% |
| EPS (Diluted) | -$1.31 | +29.9% | +39.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.9M | -30.7% | -11.5% |
| Current Assets | $4.1M | -31.7% | -12.7% |
| Total Assets | $4.1M | -31.6% | -12.6% |
| Current Liabilities | $1.4M | -19.5% | +6.8% |
| Total Liabilities | $1.4M | -19.5% | +6.8% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$10.0M | — | — |
| Capital Expenditures | $5K | — | — |
| Investing Cash Flow | -$5K | — | — |
| Financing Cash Flow | $3.9M | — | — |
| Free Cash Flow | -$10.0M | — | — |
| $2.7M |
| -36.4% |
| -19.9% |